Investing.com - Goodrx (NASDAQ: GDRX) reported third quarter EPS of $0.08, worse than the analyst estimate of $0.09. Revenue for the quarter came in at $195.3M versus the consensus estimate of $195.66M.
Guidance
Goodrx sees Q4 2024 revenue of $200.00M versus the analyst consensus of $206.20M.
Goodrx sees FY 2024 revenue of $794.00M versus the analyst consensus of $800.70M.
Goodrx's stock price closed at $6.11. It is down -15.26% in the last 3 months and up 11.70% in the last 12 months.
Goodrx saw 0 positive EPS revisions and 8 negative EPS revisions in the last 90 days. See Goodrx's stock price’s past reactions to earnings here.
According to InvestingPro, Goodrx's Financial Health score is "good performance".
Check out Goodrx's recent earnings performance, and Goodrx's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar